Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: 2018

Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018

20180418 AACR 2018 poster PCPV – EN

Published 18 April 2018
Categorized as 2018, Press release

TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma

Johann Foloppe, et al. International Oncolytic Virus Conference, April 2018 Download the poster here Poster Presentation

Published 17 April 2018
Categorized as -others, 2018, Publication, TG6002

Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses

20180321-Resultats-2017-EN

Published 21 March 2018
Categorized as 2018, Press release

Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018

20180315 PR AACR LB poster accepted

Published 15 March 2018
Categorized as 2018, Press release

First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)

20180117 PR FPI T101

Published 17 January 2018
Categorized as 2018, Press release, TG1050

First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)

20180116 PR FPI TG4010 1L EN

Published 16 January 2018
Categorized as 2018, Press release, TG4010

TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B

Martin F. Sprinzl, et al. AASLD & Hepatology, October 2017 Download the poster here Poster Presentation

Published 23 October 2017
Categorized as -others, 2018, Publication, TG1050

Posts pagination

Newer posts Page 1 … Page 4
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu